CRISPR Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2013)

Organization Overview

First Clinical Trial
2018
NCT03655678
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CRISPR Therapeutics | CRISPR Therapeutics AG